A new study published JAMA Ophthalmology has brought attention to a series of vision problems observed in patients taking ...

"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in ...

Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained ...

Topline results from our Phase 2 BMT-801 'signal detection' clinical study with MC4R agonist bremelanotide plus a glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist ...

What is stenosis after gastric bypass surgery? After gastric bypass surgery for weight loss, the new connection between the stomach pouch and the small intestine may narrow. This is called an ...

They act by targeting the incretin hormones-glucagon like peptide1 receptor (GLP-1R) and glucose dependent insulinotropic polypeptide/Gastric inhibitory polypeptide receptor (GIP-R). It is ...